Intragastric Balloon Treatment for Obesity: FDA Safety Updates

Chinara M. Tate, Allan Geliebter

Research output: Contribution to journalComment/debate

17 Scopus citations


Over the past year, the FDA has issued two letters to healthcare providers alerting them to adverse events associated with ORBERA and ReShape intragastric balloons (IGBs), including several deaths. Both IGB devices were FDA-approved for use in the US in the summer of 2015. Although the adverse events cited in the two letters occurred following FDA approval, there was already evidence prior to FDA approval that the safety and efficacy of ReShape and ORBERA were highly questionable. Since January 1, 2006, ORBERA and Reshape IGB have been implicated in 33 deaths. Given the cited evidence, we recommend FDA withdrawal of these two devices.

Original languageEnglish
JournalAdvances in Therapy
Issue number1
StatePublished - 1 Jan 2018


  • Bariatric surgery
  • Endoscopy
  • Gastric capacity
  • Gastric distension
  • Obesity
  • Obesity treatment
  • Qsymia
  • Weight loss


Dive into the research topics of 'Intragastric Balloon Treatment for Obesity: FDA Safety Updates'. Together they form a unique fingerprint.

Cite this